Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6384-6390

  Phillips, Roger M ^a   Burger, Angelika M ^b   Loadman, Paul M ^a   Jarrett, Claire M ^a   Swaine, David J ^a   Fiebig, Heinz Herbert ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TISSUE HOMOGENATE; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, NUDE; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; PREDICTIVE VALUE OF TESTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033709414     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. A critical appraisal of the human tumor stem cell assay
2. He's not going to talk about in vitro predictive assays again is he?
3. Selection of markers to predict tumor response or survival: Description of a novel approach
4. Enzyme directed bioreductive drug development
5. Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer drags and quinone metabolizing enzymes, particularly DT-diaphorase
6. Mitomycin C: A prototype bioreductive agent
7. Reductive activation of mitomycin C and mitomycin C metabolites by NADPH-cytochrome P450 reductase and xanthine oxidase
8. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C induced DNA damage and cytotoxicity in human colon carcinoma cells
9. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors
10. 5 reductase
11. Non-enzymatic and enzymatic activation of mitomycin C: Identification of a unique cytosolic activity
12. Enzymology of mitomycin C metabolic activation in tumor tissue: Characterization of a novel mitochondrial reductase
13. Mechanism of hypoxic and aerobic toxicity of mitomycin C in Chinese hamster V79 cells
14. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome P-450 reductase
15. Enzymology of bioreductive drug activation
16. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone acceptor) oxidoreductase
17. pH dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin
18. Bioactivation of mitomycin C antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase
19. Chinese hamster ovary cells resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase
20. Overexpression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone sensitivity: A questionable role for the enzyme as a target for bioreductively activated anticancer drugs
21. Increased DT-diaphorase expression and cross resistance to mitomycin C in a series of cisplatin resistant human ovarian cancer cell lines
22. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon tumor cell line that lacks DT-diaphorase
23. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9
24. The sensitivity of human tumor cells to quinone bioreductive drugs: What role for DT-diaphorase?
25. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin C
26. Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells: Differences in in vitro and in vivo systems
27. Pharmacological and biochemical determinants of the antitumor activity of the indoloquinone EO9
28. Enzymology of mitomycin C metabolic activation in tumor tissue. Implications for enzyme directed bioreductive drug development
29. Combined in vitrolin vivo test procedure with human tumor xenografts
30. Primary bioassay of human tumor stem cells
31. Human tumor xenografts. Predictivity, characterisation and discovery of new anticancer drugs
32. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (ed. 2)
33. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
34. A rapid and sensitive method for the quantification of microgram quantifies of protein utilizing the principle of protein-dye binding
35. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
36. An information-intensive approach to the molecular pharmacology of cancer
37. Determination of mitomycin C,2,7-diaminomitosene, 1,2-cis- and 1,2-trans-1-hydroxy-2,7-diaminomitosene in tumor tissue by high performance liquid chromatography
38. Relationship between NAD(P)H:quinone oxidoreductase I (NQOI) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones
39. An isogenic human colon model for NQOI and its application in determining the role of DT-diaphorase in the antitumor activity of a range of quinone based agents
40. Re-evaluation of the molecular pharmacology of mitomycin C
41. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C
42. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins
43. Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA
44. The multiple roles of tumor stroma
45. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation
46. A critical appraisal of the predictive value of in vitro chemosensitivity assays